Rare and Orphan Disease Conference

ABOUT THE EVENT

Attendees of the 2.5-day conference, including patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists, will leave with an understanding of:

•  C-Path’s Rare and Orphan Disease Program’s current and future impact on drug development in rare diseases from the perspectives of patients, regulators and industry partners
•  The Critical Path for Rare Neurodegenerative Disease (CP-RND) initiative’s first year impact and highlights
• How RDCA-DAP has been enhanced in the last year, and how the platform informs rare disease drug development
•  Transversal solutions to address bottlenecks in drug development